Table 1 Patient characteristics
Characteristics | n = 21 |
|---|---|
Age | Median 68 (38–84) |
Gender | |
Male | 12 (57%) |
Female | 9 (43%) |
Primary tumour location | |
Right | 9 (43%) |
Left | 12 (57%) |
Resection | |
Concurrent | 5 (24%) |
Subsequent – liver first | 5 (24%) |
Subsequent – primary first | 11 (52%) |
Time between resections | Median 36 days |
Treatment | |
Chemonaïve | 11 (52%) |
Both tumours | 7 (33%) |
Only metastasis | 2 (10%) |
Only primary | 1 (5%) |
Neoadjuvant treatment | |
CAPOX | 2 (10%) |
CAPOX + bevacizumab | 2 (10%) |
FOLFIRI + cetuximab | 1 (5%) |
FOLFOX + cetuximab | 2 (10%) |
Between resections | |
CAPOX | 2 (10%) |
FOLFOX | 1 (5%) |
Number metastases | Median 2 (1–5) |
Microsatellite stability | 21 (100%) |
Tumour stage | |
Stage IV | 21 (100%) |
Tumour differentiation | |
Low | 2 (10%) |
High | 19 (90%) |